ダウンロード数 : ?
ファイル
言語
英語
属性
総説
著者
石原 俊治 医学部内科学講座内科学第二
三島 義之 医学部内科学講座内科学第二
川島 耕作 医学部内科学講座内科学第二
内容記述(抄録等)
Crohn’s disease (CD) is an immune-mediated inflammatory intestinal disease of unknown etiology. In addition to conventional drugs such as 5-aminosalicylates (5-ASA), corticosteroids, and immune-modulating drugs, biologics targeting inflammation- and immunerelated molecules have been developed for treating CD. Initially, anti-tumor necrosis factor (TNF)-α antibodies were used for induction and maintenance therapies, and the clinical course of affected patients was dramatically changed because of their efficacy and safety. More recently, novel humanized biologics targeting the p40-subunit of interleukin (IL)-12/23 and α4β7-integrin have been developed, and shown to contribute to longterm therapy for CD. Although the efficacy of biologics for CD is widely recognized, how to determine which biologic is appropriate for individual patients remains largely unknown and additional studies are necessary to clarify this issue.
主題
cystatin C
protease inhibitor
cerebrospinal fluid
inflammatory neurological diseases
neurodegenerative diseases
掲載誌名
Shimane Journal of Medical Science
37
2
開始ページ
45
終了ページ
50
ISSN
03865959
ISSN(Online)
24332410
発行日
2020-06
NCID
AA00841586
DOI
DOI(SelfDOI)
出版者
Faculty of Medicine, Shimane University
出版者別表記
島根大学医学部
資料タイプ
紀要論文
ファイル形式
PDF
権利関係
Faculty of Medicine, Shimane University
著者版/出版社版
出版社版
部局
医学部
他の一覧
このエントリーをはてなブックマークに追加